Si Mou

Lead function to support translational and clinical efforts leveraging novel mass spec-based platforms for clinical biomarker discovery and clinical validation, drug MOA/MOR, target selection/validation, and drug safety investigations in disease area such as oncology, immunology etc.

- Support preclinical/clinical biomarker discovery using proteomics/metabolomics approach; development of protein clinical biomarkers in plasma/sputum/cell extract to understand disease/tox MOAs, safety or patient selection. - Support in-house and CRO out-sourcing preclinical, GLP, and clinical PK or TK analysis of novel therapeutic modalities such as ADCs, bispecifics, and lipidated peptides to inform decisions for preclinical/clinical development - Developed investigational MOA studies of formulation excipients toxicity (using cells-based assays and targeted metabolomic LC-MS/MS) for preclinical safety findings which demonstrated safety margins in clinical studies and successfully supported IND filing - Established novel bioanalytical platform for intact analysis of biotherapeutics such as ADCs to understand DAR (drug-to-antibody ratio) distribution and biotransformations in vivo

• Developed multiplexed and highly sensitive biomarker assay to quantitate over 30 protein biomarkers in a DNA damage signaling pathway for breast and prostate cancer • Developed a targeted metabolomic platform with ~300 polar metabolites in human plasma or tissue using metabolite standards; the platform was applied to differentiate multiple classified cancer samples • Built a high resolution accurate mass metabolite spectral library for over 300 metabolite compounds for untargeted metabolite identification which covers over 20 major biochemical pathways • Developed a Data Independent MS acquisition (SWATH) performance kit for peptide mapping and protein quantitative analysis in biological matrix • Developed and patented for a targeted LC-MS method for characterizing tissue protein biomarker in food applications which was used to differentiate authentic and fake meat

• Developed kinase-substrate kinetics assay using CE-MS to achieve an efficient and simple method for kinase study • Built up an automated diagonal CE-MS system with online microreactors, which was applied to fast and accurate quantitative analysis of protein modifications • Optimized CE-ESI-MS system for peptide mapping, greatly improving its sensitivity

• Supervised Instrumental Analysis Laboratory class for first-year graduate students • Designed and wrote lab manuals for the class • Taught ELISA, peptide mapping, HPLC-MS and troubleshooting skills

• Instructed for an introductory chemistry laboratory section of 20+ students • Graded laboratory reports, presented solutions to problems, and answered student questions

• Built a native CE-ESI-MS interface connecting a CE system to a mass spectrometer to separate and characterize antibody charge variants • Achieved separation and characterization of monoclonal antibody and charge heterogenetic products using a wide variety of analytical techniques such as LC-MS and CE-MS. • Joined and published in an international inter-company study on the robustness of CE-MS for peptide analysis • Assisted in multiple projects for protein analytical method development